BlueWillow Biologics is a privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines, based on its patented nanotechnology platform.
The company was originally founded as NanoBio Corporation, a spin-off from the Center for Biologic Nanotechnology at the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation and NIH contracts, the company underwent a strategic “pivot” in 2016–17 to refocus its nanotechnology platform on the development of intranasal vaccines for respiratory and sexually transmitted diseases.
BlueWillow’s lead product candidates include intranasal vaccines for RSV, seasonal and pandemic influenza, pertussis, anthrax, HSV-2 and chlamydia. The company’s NanoVax™ technology platform utilizes a novel oil-in-water emulsion adjuvant to enable intranasal vaccines that elicit both systemic and mucosal immunity. BlueWillow’s vaccines uniquely elicit mucosal antibodies that serve as “bouncers at the door” as the body’s first line of defense to keep infections out.
In addition to its vaccine programs, BlueWillow has continued to advance certain novel dermatology and drug delivery applications through partnerships under the company’s NanoBio™ division. BlueWillow’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.